The common stock is listed on the Nasdaq Global Select Market

Davis Polk advised the representatives of the several underwriters in connection with a public offering by IDEAYA Biosciences, Inc. of 8,355,714 shares of common stock at $35.00 per share and pre-funded warrants to purchase 285,715 shares of common stock at $34.9999 per pre-funded warrant, which included 1,127,142 shares of common stock from the full exercise of the underwriters’ option to purchase additional shares, for total gross proceeds of approximately $302.5 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “IDYA.”

Based in South San Francisco, California, IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Jonathan Bye and Eddie Magana. The tax team included partner Mario J. Verdolini and associates William Liang and Ryan Powers. The intellectual property team included partner David R. Bauer and associate Austin Fuss. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post